At the news
? NEUTRALIMPACT 4/10 EFFECT filed Jul 22, 2026 at 00:15 ET
Lyell Immunopharma's S-3 shelf registration (File No. 333-297433) became effective on July 21, 2026. This allows selling stockholders to resell up to 1,952,360 shares of common stock acquired in a March 2026 private placement. The company receives no proceeds from these sales, but the effectiveness introduces a potential overhang of ~1.95M shares that can be sold into the market at any time, representing approximately 0.6% of the current market cap of $321M, a modest but real dilution risk for a pre-revenue biotech with limited liquidity.
- S-3 shelf registration (File No. 333-297433) became effective on July 21, 2026.
- Registration covers resale of 1,952,360 shares of common stock by selling stockholders.
- Selling stockholders include institutional investors ARCH Venture Fund, Gates Frontier, and Explore Investments.
- Lyell Immunopharma will not receive any proceeds from these share sales.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access